f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Alto US and OUS Post-Approval Study


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Ongoing
Application Number /
Requirement Number		 P120006 S031/ PAS002
Date Original Protocol Accepted 10/09/2020
Date Current Protocol Accepted  
Study Name Alto US and OUS Post-Approval Study
Device Name Alto Abdominal Stent Graft System
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives Objective of this post-approval study is to collect safety, effectiveness, and neck dilatation data on Alto Abdominal Stent Graft System for the endovascular treatment of infrarenal abdominal aortic aneurysms and evaluate real-world outcomes in comparison to commercially available comparator devices.
Study Population The study population is patients with an infrarenal abdominal aortic aneurysm who met the anatomic criteria for implantation with the Alto device according to clinical guidelines and the treating physician’s judgement. Notably, treating physiscians will be making the determination regarding whether a subject should be enrolled and treated; they may request input from the Endologix Imaging Services.
Sample Size A minimum of 450 consented patients diagnosed with AAA who are considered candidates for endovascular repair and meet the study eligibility criteria. At least 300 will be allocated to the Alto cohort, and 150 to the comparator group.
Key Study Endpoints There are two primary endpoints: a clinical endpoint and a surrogate. The clinical endpoint is a composite of aneurysm-related complications (ARC), and consists of freedom from device-related interventions (for Type I & III endoleaks, stenosis/occlusion, migration, or other device-related cause), conversion to open surgery, Type I and III endoleaks, device migration (>10 mm), aneurysm sac enlargement (>5 mm), occlusion, aneurysm rupture, and aneurysm-related death. The surrogate is the hypothesized physiologic mechanism that leads to failure of several components within the clinical endpoint: proximal neck dilation over time. The surrogate allows for an early insight into eventual clinical sequelae.

All individual components of the primary endpoint will be evaluated as separate outcomes using the Kaplan-Meier approach. Results will be stratified by device cohort.
Follow-up Visits and Length of Follow-up Subjects will be followed for 5 years.


Alto US and OUS Post-Approval Study Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 09/11/2020 09/11/2020 On Time
1 year report 03/13/2021 03/11/2021 On Time
quarterly report 05/28/2021 05/28/2021 On Time
quarterly report 08/28/2021 08/25/2021 On Time
18 month report 09/11/2021 09/10/2021 On Time
2 year report 03/13/2022 03/11/2022 On Time
30 month report 09/13/2022 09/23/2022 Overdue/Received
quarterly report 03/13/2023 02/24/2023 On Time
3 year report 04/13/2023 04/13/2023 On Time
quarterly leaks report 06/13/2023 05/24/2023 On Time
42 month report 09/13/2023 09/13/2023 On Time
quarterly report 11/15/2023 11/14/2023 On Time
4 year report 03/12/2024 03/12/2024 On Time
5 year report 03/12/2025    


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-